Diagnostic challenges for rapid human immunodeficiency virus assays: Performance using HIV-1 group O, HIV-1 group M, and HIV-2 samples

Journal of Human Virology

Volumn 1, Issue 1, 1997, Pages 45-51

  Constantine, Niel T ^a,f   Zekeng, Leopold ^b   Sangare, Affoue K ^c   Gurtler, Lutz ^d   Saville, Rebecca ^a   Anhary, Hamid ^a   Wild, Carl ^e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b National AIDS Program   (Cameroon)

^c INSTITUT PASTEUR DE CÔTE D'IVOIRE   (Côte d’Ivoire)

^d UNIVERSITY OF MUNICH   (Germany)

^e Biotech Research Laboratories   (United States)

^f UNIVERSITY OF MARYLAND   (United States)

Author keywords

Evaluation; HIV 1 group O; HIV 2; Rapid assays

Indexed keywords

ANALYTICAL EQUIPMENT; ARTICLE; BLOOD; CLASSIFICATION; EVALUATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; ISOLATION AND PURIFICATION; METHODOLOGY; SENSITIVITY AND SPECIFICITY; SEROTYPING; VIROLOGY;

EVALUATION STUDIES; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; IMMUNOASSAY; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; SEROTYPING;

EID: 0031261055     PISSN: 10909508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Constantine NT, Callahan JD, Watts DM. Retroviral testing: essentials for quality control and laboratory diagnosis. Boca Raton, FL: CRC Press, 1992:1-228.
2. Healey DS, Dax EM. An evaluation of two simple synthetic peptide based anti-HIV assays. J Virol Methods 1992;38:305-312.
3. Constantine NT, Fox E, Abbatte EA, et al. Diagnostic usefulness of five screening assays for HIV in an east African city where prevalence of infection is low. 1989;3:313-317.
4. World Health Organization. Revised recommendations for the selection and use of HIV antibody tests. Wkly Epidemiol Rec 1997;72:81-88.
5. Constantine NT. HIV testing revisited. Advance 1995;4: 16-25.
6. Centers for Disease Control and Prevention. Provisional Public health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR Morb Mortal Wkly Rep 1996;45:468-480.
7. Murex Diagnostics. CDC recommends treating occupational HIV exposure within 2 hours. Techline 1997;4:1-3.
8. Gurtler LG, Zekeng L, Simon F, et al. Reactivity of five anti-HIV-1 subtype O specimens with six different anti-HIV screening ELISAs and three immunoblots. J Virol Method 1995;51:177-184.
9. Hu DJ, Dondero TJ, Rayfield MA, et al. The emerging genetic diversity of HIV. JAMA 1996;275:210-216.
10. Callahan JD, Constantine NT, Watts DM. More support for the use of HIV-1/2 combination assays. J Virol Methods 1990;28:217-218.
11. Food and Drug Administration. Revised recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Rockville, MD: Center for Biologies Evaluation and Research, 1992:23.
12. Zekeng L, Gurtler L, Afane AE, et al. Prevalence of HIV-1 subtype O infection in Cameroon: preliminary results. AIDS 1994;8:1626-1628.
13. Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994;343:1393-1394.
14. Schable C, Zekeng L, Pau C, et al. Sensitivity of United states HIV antibody tests for detection of HIV-1 group O infections. Lancet 1994;344:1333-1334.
15. Simon F, Ly TD, Baillou-Beaufils A, et al. Sensitivity of screening kits for anti-HIV-1 subtype O antibodies. AIDS 1994;8:1628-1629.
16. Centers for Disease Control and Prevention. Identification of HIV-1 group O infection - Los Angeles County, CA, 1996. MMWR Morb Mortal Wkly Rep 1996;45:561-565.
17. U.S. Food and Drug Administration. Letter to manufacturers, HFM-310. Rockville, MD: Center for Biologies Evaluation and Research, July 30, 1997.
18. Phillips SK, Granade TC, Parekh B, et al. Ability of current rapid HIV antibody assays to identify sera from individuals infected with HIV-1 subtypes A-E, group O, and HIV-2 [abstract V-65]. Presented at the American Society of Microbiologists Annual Meeting, Miami, FL, May 1997.
19. Pau C-P, Lee-Thomas S, Auwanit W, et al. Highly specific V3 peptide enzyme immunoassay for serotyping HIV-1 specimens from Thailand. AIDS 1993;7:337-340.
20. World Health Organization. Operational characteristics of commercially available assays to detect antibodies to HIV-1 and/or HIV-2 in human sera. Report no. 8. Geneva: World health Organization, 1994:1-47.
21. Constantine NT, van der Groen G, Belsey E, et al. Sensitivity of HIV antibody assays as determined by seroconversion panels. AIDS 1994;8:1715-1720.
22. Hyams KC, Okoth FA, Tukei PM, et al. Inconclusive hepatitis C virus antibody results in African serum. J Infect Dis 1993;167:254-255.
23. Callahan JD, Constantine NT, Kataaha P, et al. Second generation hepatitis C virus assays: performance when testing African sera. J Med Virol 1993;41:35-38.
24. Dondero TJ, Dale JH, George JR. HIV-1 variants: yet another challenge to public health. Lancet 1994;343:1376.